Amazon Biotech has successfully negotiated a Phase I/II protocol with the FDA. This allows the company to move forward with implementation of its filed Phase I/II trial of its proprietary AMZ0026 therapy in HIV-positive patients.
The approved protocol is designed to test the safety, immunological and antiviral effects of AMZ0026, the company's anti-HIV parent formula. The double-blind, placebo-controlled clinical trial design involves 32 non-symptomatic HIV subjects who have yet to be treated with Highly Active Anti-Retroviral Therapy (HAART).